Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$106.44 USD

106.44
1,088,790

-1.65 (-1.53%)

Updated Jul 30, 2024 04:00 PM ET

After-Market: $106.33 -0.11 (-0.10%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat

Inogen's (INGN) first-quarter results benefit from higher revenues across the majority of its geographical segments and categories.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vince Surgical System. Higher production costs are a woe.

OPKO Health (OPK) Post In-Line Q1 Earnings, Revenues Top

OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.

Looking for a Growth Stock? 3 Reasons Why Masimo (MASI) is a Solid Choice

Masimo (MASI) possesses solid growth attributes, which could help it handily outperform the market.

Masimo (MASI) Upgraded to Buy: Here's What You Should Know

Masimo (MASI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Masimo's (MASI) Q1 Earnings Surpass Estimates, FY22 View Up

Masimo's (MASI) robust product shipments drive its Q1 sales.

Masimo (MASI) Q1 Earnings and Revenues Surpass Estimates

Masimo (MASI) delivered earnings and revenue surprises of 1.09% and 3.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SeaSpine (SPNE) Moves 5.8% Higher: Will This Strength Last?

SeaSpine (SPNE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Masimo's (MASI) Sound United Buyout to Boost Product Portfolio

Masimo's (MASI) completion of Sound United's buyout to help enhance the former's extended portfolio of hospital and home medical technology solutions.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Masimo (MASI) Reports Preliminary Q1 Results, Reiterates '22 View

Masimo's (MASI) first-quarter 2022 results are likely to have been dampened by supply chain headwinds.

Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of -17.65% and 3.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Announces Favorable Study Results on SpHb

Masimo's (MASI) SpHb is likely to enhance perioperative transfusion management and post-operative patient outcomes on pediatric patients.

Venus Concept (VERO) Reports Q4 Loss, Tops Revenue Estimates

Venus Concept (VERO) delivered earnings and revenue surprises of 33.33% and 0.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Masimo's (MASI) New Product Expansion to Boost Patient Outcome

Masimo's (MASI) latest feature additions to its telehealth for Patient SafetyNet are likely to significantly improve patient outcomes.

Why Is Masimo (MASI) Up 3.6% Since Last Earnings Report?

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Strength Seen in Masimo (MASI): Can Its 7.7% Jump Turn into More Strength?

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why You Should Retain Masimo (MASI) Stock For Now

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.

Masimo's (MASI) SedLine Receives FDA's Pediatric Indication

The latest FDA clearance for Masimo's (MASI) SedLine is likely to improve brain function monitoring in pediatric patients.

Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up

Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.

Masimo (MASI) Q4 Earnings and Revenues Surpass Estimates

Masimo (MASI) delivered earnings and revenue surprises of 10% and 2.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo (MASI) Stock Jumps 6%: Will It Continue to Soar?

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Allscripts (MDRX) Reports Solid Preliminary Q4 Revenues

Allscripts' (MDRX) revenue growth in the fourth quarter is likely to have been boosted by solid segmental performances.